Search Results - the PROMISE-Micro Study Group

  • Showing 1 - 2 results of 2
Refine Results
  1. 1

    Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment by Sarah J. Morgan, Ellis Coulter, Hannah L. Betts, George M. Solomon, John P. Clancy, Steven M. Rowe, David P. Nichols, Pradeep K. Singh, the PROMISE-Micro Study Group

    Published in The Journal of Clinical Investigation (2024-10-01)
    Get full text
    Article


  2. 2

    Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist by David P. Nichols, Sarah J. Morgan, Michelle Skalland, Anh T. Vo, Jill M. Van Dalfsen, Sachinkumar B.P. Singh, Wendy Ni, Lucas R. Hoffman, Kailee McGeer, Sonya L. Heltshe, John P. Clancy, Steven M. Rowe, Peter Jorth, Pradeep K. Singh, the PROMISE-Micro Study Group

    Published in The Journal of Clinical Investigation (2023-05-01)
    Get full text
    Article


Search Tools: